Last reviewed · How we verify

Intracystic injection of OK432 under US guiding

Carmel Medical Center · FDA-approved active Small molecule Quality 2/100

Intracystic injection of OK432 under US guiding is a Small molecule drug developed by Carmel Medical Center. It is currently FDA-approved. Also known as: OK432 (Picibanil).

At a glance

Generic nameIntracystic injection of OK432 under US guiding
Also known asOK432 (Picibanil)
SponsorCarmel Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intracystic injection of OK432 under US guiding

What is Intracystic injection of OK432 under US guiding?

Intracystic injection of OK432 under US guiding is a Small molecule drug developed by Carmel Medical Center.

Who makes Intracystic injection of OK432 under US guiding?

Intracystic injection of OK432 under US guiding is developed and marketed by Carmel Medical Center (see full Carmel Medical Center pipeline at /company/carmel-medical-center).

Is Intracystic injection of OK432 under US guiding also known as anything else?

Intracystic injection of OK432 under US guiding is also known as OK432 (Picibanil).

What development phase is Intracystic injection of OK432 under US guiding in?

Intracystic injection of OK432 under US guiding is FDA-approved (marketed).

Related